<DOC>
	<DOCNO>NCT02417389</DOCNO>
	<brief_summary>To assess efficacy safety treatment cinacalcet cinacalcet plus alendronate control bone loss induce primary hyperparathyroidism .</brief_summary>
	<brief_title>Efficacy Cinacalcet Control Primary Hyperparathyroidism</brief_title>
	<detailed_description>The project conduct Istituto Auxologico Italiano , IRCCS , Milano ( Italy ) . Principal Investigator : Maria Luisa Bianchi , M.D. , Nephrologist , Bone Metabolism Unit , Istituto Auxologico Italiano IRCCS , Milan , Italy Other investigator : Silvia Vai , M.D. , endocrinologist , Bone Metabolism Unit , Istituto Auxologico Italiano IRCCS , Milan , Italy Francesca Broggi , Dr. , biologist , Bone Metabolism Unit , Istituto Auxologico Italiano IRCCS , Milan , Italy Luca Persani , M.D. , Endocrinologist , University Milan &amp; Division Endocrine Metabolic Diseases , Istituto Auxologico Italiano IRCCS , Milan , Italy Introduction Cinacalcet orally active second-generation calcimimetic drug . Cinacalcet increase sensitivity calcium receptor locate surface parathyroid cell , thus inhibit parathyroid hormone ( PTH ) secretion ( increased hyperparathyroidism ) . Cinacalcet approve FDA EMEA use dialyze patient affected chronic renal failure uncontrolled secondary hyperparathyroidism , basis three 6-month double-blind placebo-controlled study 1,100 patient . PTH secretion parathyroid cell proliferation regulate serum level ionize calcium ( Ca++ ) . The mechanism base bind Ca++ ion G-protein couple membrane receptor ( GPCR ) , call Calcium Sensing Receptor ( CaR ) . With low circulating level Ca++ alteration calcium-receptor binding , high amount PTH secrete , hyperparathyroidism develops , long term systemic alteration ( bone mineral density ( BMD ) reduction , increase fracture risk , hypercalciuria , renal stone , hypertension , etc . ) appear . Substances calcimimetic action , Cinacalcet , recently develop . Until , Cinacalcet mainly use hyperparathyroidism secondary renal insufficiency . In condition , Cinacalcet proven effective reduce circulate PTH acceptable level , obtain normalization serum Ca++ phosphate level 50 % case . Moreover , drug usually well tolerate . Side effect ( essentially nausea vomit ) report 30 % case . Pilot study confirm efficacy Cinacalcet maintain normal calcemia long term also patient primary hyperparathyroidism ( PHP ) due adenoma carcinoma one parathyroid gland . For reason , investigator propose use Cinacalcet case PHP , surgical intervention possible , use combination oral alendronate presence osteopenia/osteoporosis . Study objectives - To assess efficacy safety long-term Cinacalcet treatment patient PHP , operable , localization parathyroid adenoma possible . - To assess efficacy combine therapy Cinacalcet alendronate control bone loss induce PHP . Study design : prospective , single-arm , 24-month study , organize two phase . During Phase 1 , patient treat Cinacalcet alone 12 month . During Phase 2 , patient treat Cinacalcet ( ) plus oral alendronate ( 70 mg weekly ) another 12 month . The study conduct accordance Good Clinical Practice ( GCP ) rule , approve Ethical Committee Istituto Auxologico Italiano , IRCCS . Timelines The study organize follow : - 10 month patient enrolment - 24 month study ( Phase 1 plus Phase 2 ) - 6 month analysis result The enrolment start approval protocol commitment manufacture Company supply Cinacalcet . Study population 22 patient PHP , operable , localization parathyroid adenoma possible , reduce bone density ( T-score ≤ -2 spine hip ) include study . All patient post-menopausal woman . Patients include study , accord pre-defined inclusion criterion ( 5 criterion must meet ) exclusion criterion ( none criterion must meet ) . Definition PHP : serum intact PTH level high 65 ng/ml least two determination 12 month start study ( exclusion severe hypovitaminosis D ) , serum calcium high 10.4 mg/dl . All patient study advance parathyroid ecography neck CT , scintigraphy Sestamibi . At time enrolment , follow exam do : 1. evaluation phosphate calcium metabolism ( blood : intact parathyroid hormone , total calcium , ionized calcium , phosphate , creatinine , 25-hydroxy-vitamin D 1,25-dihydroxy-vitamin D , bone-specific alkaline phosphatase , C-terminal telopeptide ; urine : calciuria 24-hours , phosphaturia 24-hours , N-terminal telopeptide , creatinine clearance ) 2. bone density evaluation ( DXA scan : radius , lumbar spine , proximal femur , total body ) 3. general evaluation ( liver function , blood cell count , renal function ( serum creatinine creatinine clearance ) Treatment follow-up The initial treatment regimen 30 mg Cinacalcet twice day , 12-hour interval . The follow-up do follow : - 2 week start Cinacalcet , plasma level total calcium intact PTH measure . If calcemia still 10.6 mg/dl , Cinacalcet dose double ( 60 mg twice day ) . - 4 week start Cinacalcet , follow biochemical parameter measure : blood : PTH , total calcium , ionized calcium , phosphate , creatinine , liver function , blood cell count ; urine : calciuria 24-hours , phosphaturia 24-hours , N-terminal telopeptide , creatinine clearance . If calcemia still 10.6 mg/dl , Cinacalcet dose increase 90 mg twice day . - every 8 week , follow biochemical parameter measure : blood : PTH , calcium , ionized calcium , phosphate , creatinine , liver function , blood cell count ; urine : calciuria 24-hours , phosphaturia 24-hours , N-terminal telopeptide , creatinine clearance . - 12 month Cinacalcet therapy , DXA scan repeat , oral alendronate dose 70 mg weekly add - end 24th month therapy , exams do time enrolment repeat During study , serum total calcium level decrease 8.4 mg/dl , Cinacalcet daily dose halve . If serum total calcium level still 8.4 mg/dl minimum dose Cinacalcet ( 30 mg day ) , Cinacalcet stop . In case , serum calcemia measure 1-week interval , Cinacalcet treatment resume accordingly . All patient ' data collect specially design CRF ( case report form ) . Side effect adverse reaction appropriately record CRF . The severity side effect adverse reaction evaluate order decide whether involved drug ( ) stop . Adverse event ( AE ) record dedicated section CRF , accordance standard rule clinical trial . The adverse event classify , usual , serious AE ( SAE ) non-serious AE ( AE ) . For AE severity causality record . SAEs immediately report drug manufacturer ( Amgen ) . Appropriate clinical decision ( immediate follow-up ) make . According available literature , side effect Cinacalcet generally mild . In case severe side effect SAE , treatment stop . Methods All DXA scan laboratory test perform Istituto Auxologico Italiano IRCCS . Bone mass measure dual X-ray ( DXA ) Hologic Discovery densitometer distal radius , lumbar spine , hip total body . Serum urinary calcium phosphorus measure standard method . Serum bone alkaline phosphatase ( BSAP ) measure EIA ( enzyme-linked immunosorbent assay ; Quidel , San Diego , USA ) ; serum C-terminal telopeptide ( CTx ) immunoluminescent method ( Roche Diagnostic , Monza , Italy ) ; urinary N-terminal telopeptide procollagen type I ( NTx ) EIA ( enzyme-linked immunosorbent assay ; Ostex Intern . Inc. , Seattle , USA ) . Serum intact parathyroid hormone ( PTH ) measure immunoluminescent method ( Roche Diagnostic , Monza , Italy ) ; 25-hydroxyvitamin D ( 25-OH D ) RIA ( radioimmunological assay , DiaSorin Inc , Stillwater , USA ) ; 1,25-dihydroxyvitamin D ( 1,25 ( OH ) 2 D ) radio receptor assay ( Nichols Institute Diagnostics , San Juan Capistrano , USA ) . Statistical method To evaluate sample size , follow point consider : 1 . The study focus well-characterized , homogeneous group patient affect PHP without possibility surgical removal adenoma , also affect osteopenia/osteoporosis . 2 . These patient already follow Center several year , risk drop-out low ( estimate 10 % ) . 3 . Considering characteristic study ( single-arm ) , confidence level 95 % , 5 % significance , drop-out rate 10 % , 2.5 % change BMD , sample size 16 patient calculate . On basis patient come attention , investigator estimate able enroll 20 patient meet inclusion criterion . Data express mean plus minus SD . All variable analyze evaluate normality ( Shapiro-Wilk test ) , order choose appropriate statistical test . To estimate comparison mean , evaluate validity assumption , Student 's test one-way ANOVA use . Statistical significance define p &lt; 0.05 , two-sided . At end study , occurrence adverse event analyze descriptive statistic .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Primary</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>1. patient affected moderate severe PHP without instrumental ( echography , neck CT , scintigraphy Sestamibi ) evidence parathyroid adenoma hyperplasia ; OR patient affected PHP previously surgically treat , recidivate without instrumental evidence parathyroid adenoma hyperplasia ; OR patient affected PHP judge inoperable pathology 2. patient serum total calcium 10.5 12.5 mg/dl ( inclusive ) 3. male : age ≥50 year ; female : age ≥50 year , menopause least 2 year ; 4. patient reduction bone density ( Tscore ≤ 2 spine OR hip , DXA scan ) 5. informed consent sign enrolment 1. lack informed consent ; 2. presence disease know cause hypercalcemia ( e.g . familial benign hypercalcemia ) ; 3. previous ongoing therapy interfere calcium bone metabolism ; 4. impair liver and/or renal function ( i.e . serum aspartate aminotransferase , alanine aminotransferase total bilirubin twice upper limit normal ; creatinine clearance lower 60 ml/min ) ; 5. history seizure , malignancy , myocardial infarction ; 6. previous exposure cinacalcet .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>primary hyperparathyroidism</keyword>
	<keyword>hypercalcemia</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>bone turnover</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>fracture</keyword>
</DOC>